These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 15113578)
1. Optimisation of powders for pulmonary delivery using supercritical fluid technology. Rehman M; Shekunov BY; York P; Lechuga-Ballesteros D; Miller DP; Tan T; Colthorpe P Eur J Pharm Sci; 2004 May; 22(1):1-17. PubMed ID: 15113578 [TBL] [Abstract][Full Text] [Related]
2. Comparison of physical and inhalation properties of spray-dried and micronized terbutaline sulphate. Thi TH; Danède F; Descamps M; Flament MP Eur J Pharm Biopharm; 2008 Sep; 70(1):380-8. PubMed ID: 18504120 [TBL] [Abstract][Full Text] [Related]
3. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers. Zeng XM; MacRitchie HB; Marriott C; Martin GP Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863 [TBL] [Abstract][Full Text] [Related]
4. Physical characteristics and aerosol performance of naringin dry powders for pulmonary delivery prepared by spray-drying. Sansone F; Aquino RP; Del Gaudio P; Colombo P; Russo P Eur J Pharm Biopharm; 2009 May; 72(1):206-13. PubMed ID: 18996478 [TBL] [Abstract][Full Text] [Related]
5. Investigations on particle surface characteristics vs. dispersion behaviour of L-leucine coated carrier-free inhalable powders. Raula J; Thielmann F; Naderi M; Lehto VP; Kauppinen EI Int J Pharm; 2010 Jan; 385(1-2):79-85. PubMed ID: 19879344 [TBL] [Abstract][Full Text] [Related]
6. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler. de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246 [TBL] [Abstract][Full Text] [Related]
7. A novel method for the production of crystalline micronised particles. Muhammad SA; Langrish T; Tang P; Adi H; Chan HK; Kazarian SG; Dehghani F Int J Pharm; 2010 Mar; 388(1-2):114-22. PubMed ID: 20043982 [TBL] [Abstract][Full Text] [Related]
8. Particle engineering using sonocrystallization: salbutamol sulphate for pulmonary delivery. Dhumal RS; Biradar SV; Paradkar AR; York P Int J Pharm; 2009 Feb; 368(1-2):129-37. PubMed ID: 18996462 [TBL] [Abstract][Full Text] [Related]
9. Influence of the lactose grade within dry powder formulations of fluticasone propionate and terbutaline sulphate. Le VN; Bierend H; Robins E; Steckel H; Flament MP Int J Pharm; 2012 Jan; 422(1-2):75-82. PubMed ID: 22036653 [TBL] [Abstract][Full Text] [Related]
10. Aerosolization behavior of carrier-free L-leucine coated salbutamol sulphate powders. Raula J; Lähde A; Kauppinen EI Int J Pharm; 2009 Jan; 365(1-2):18-25. PubMed ID: 18789380 [TBL] [Abstract][Full Text] [Related]
11. Inhalation performance of pollen-shape carrier in dry powder formulation with different drug mixing ratios: comparison with lactose carrier. Hassan MS; Lau R Int J Pharm; 2010 Feb; 386(1-2):6-14. PubMed ID: 19922775 [TBL] [Abstract][Full Text] [Related]
12. Influence of process parameters in the ASES process on particle properties of budesonide for pulmonary delivery. Steckel H; Pichert L; Müller BW Eur J Pharm Biopharm; 2004 May; 57(3):507-12. PubMed ID: 15093600 [TBL] [Abstract][Full Text] [Related]
13. Effect of milling and sieving on functionality of dry powder inhalation products. Steckel H; Markefka P; teWierik H; Kammelar R Int J Pharm; 2006 Feb; 309(1-2):51-9. PubMed ID: 16377105 [TBL] [Abstract][Full Text] [Related]
14. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations. Marriott C; MacRitchie HB; Zeng XM; Martin GP Int J Pharm; 2006 Dec; 326(1-2):39-49. PubMed ID: 16942848 [TBL] [Abstract][Full Text] [Related]
15. Following mechanical activation of salbutamol sulphate during ball-milling with isothermal calorimetry. Gaisford S; Dennison M; Tawfik M; Jones MD Int J Pharm; 2010 Jun; 393(1-2):74-8. PubMed ID: 20385222 [TBL] [Abstract][Full Text] [Related]
16. Characterisation and aerosolisation of mannitol particles produced via confined liquid impinging jets. Tang P; Chan HK; Chiou H; Ogawa K; Jones MD; Adi H; Buckton G; Prud'homme RK; Raper JA Int J Pharm; 2009 Feb; 367(1-2):51-7. PubMed ID: 18848874 [TBL] [Abstract][Full Text] [Related]
17. Production of cromolyn sodium microparticles for aerosol delivery by supercritical assisted atomization. Reverchon E; Adami R; Caputo G AAPS PharmSciTech; 2007 Dec; 8(4):E114. PubMed ID: 18181535 [TBL] [Abstract][Full Text] [Related]
18. Air permeability of powder: a potential tool for Dry Powder Inhaler formulation development. Le VN; Robins E; Flament MP Eur J Pharm Biopharm; 2010 Nov; 76(3):464-9. PubMed ID: 20854906 [TBL] [Abstract][Full Text] [Related]
19. Crystallization of progesterone for pulmonary drug delivery. Ragab D; Rohani S; Samaha MW; El-Khawas FM; El-Maradny HA J Pharm Sci; 2010 Mar; 99(3):1123-37. PubMed ID: 19691108 [TBL] [Abstract][Full Text] [Related]
20. Influence of primary crystallisation conditions on the mechanical and interfacial properties of micronised budesonide for dry powder inhalation. Kubavat HA; Shur J; Ruecroft G; Hipkiss D; Price R Int J Pharm; 2012 Jul; 430(1-2):26-33. PubMed ID: 22449413 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]